Results 211 to 220 of about 1,468,461 (396)

Mechanism‐Based Modeling Approaches to Quantify the Effect of Immunogenicity on the Pharmacokinetics of Therapeutic Proteins in Drug Development

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Therapeutic protein administration in both preclinical and clinical studies can result in the formation of anti‐drug antibodies against the therapeutic protein. Anti‐drug antibody formation may alter the pharmacokinetics of the therapeutic protein, reduce its plasma concentrations, increase exposure variability, and may lead to a loss of ...
Paridhi Gupta   +3 more
wiley   +1 more source

Targeting of peripheral blood T lymphocytes [PDF]

open access: yes, 1996
Bolhuis, R.L.H. (Reinder)   +2 more
core   +1 more source

A recombinant bispecific single‐chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells [PDF]

open access: hybrid, 2004
Joerg Bruenke   +12 more
openalex   +1 more source

Potential roles of antibodies with different classes in IgG4‐related diseases

open access: yesRheumatology &Autoimmunity, EarlyView.
This review discussed the common characteristics of different classes of antibodies and their potential corresponding unique mechanisms involved in immunoglobulin G4‐related disease. Abstract Immunoglobulin G4‐related disease (IgG4‐RD), first identified two decades ago, is an immune‐mediated pro‐inflammatory and profibrotic disease entity affecting ...
Ling Li   +6 more
wiley   +1 more source

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC

open access: yesVIEW, EarlyView.
Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li   +10 more
wiley   +1 more source

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

open access: yesAllergy, EarlyView.
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy   +17 more
wiley   +1 more source

IgG4‐Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets

open access: yesAllergy, EarlyView.
ABSTRACT IgG4, the least abundant IgG subclass in humans, is increasingly recognised for its involvement in allergic and autoimmune pathologies. Its unique properties, such as the tendency to form half‐molecules (one heavy chain and one light chain) and its generally non‐inflammatory nature, distinguish it from other IgG subclasses.
Louisa Tedesco   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy